PMID- 12591971
OWN - NLM
STAT- MEDLINE
DCOM- 20030805
LR  - 20141120
IS  - 0893-3952 (Print)
IS  - 0893-3952 (Linking)
VI  - 16
IP  - 2
DP  - 2003 Feb
TI  - Current perspectives on HER2 testing: a review of national testing guidelines.
PG  - 173-82
AB  - Knowledge of HER2 status is a prerequisite when considering a patient's 
      eligibility for Herceptin (trastuzumab) therapy. Accurate assessment of HER2 
      status is essential to ensure that all patients who may benefit from Herceptin 
      are correctly identified. There are several assays available to determine HER2 
      status: the most common in routine clinical practice are immunohistochemistry 
      (IHC) and fluorescence in situ hybridization (FISH). Various factors can affect 
      the results achieved with these assays, including the assay antibody/probe, the 
      methodology and the experience of personnel. Many countries have implemented 
      national testing guidelines in an attempt to standardize testing procedures and 
      make results more accurate. These guidelines vary in the level of detail and the 
      number of recommendations. This review looks at areas of consensus between the 
      different national testing guidelines and highlights where errors may arise 
      during the testing procedure. The key point underlined by this review is that 
      whatever method is used to test for HER2 status, the technology must be validated 
      first, and there must be regular internal and external quality control and 
      quality assurance procedures.
FAU - Bilous, Michael
AU  - Bilous M
AD  - Institute of Clinical Pathology and Medical Research, Westmead Hospital, 
      Westmead, New South Wales, Australia.
FAU - Dowsett, Mitch
AU  - Dowsett M
FAU - Hanna, Wedad
AU  - Hanna W
FAU - Isola, Jorma
AU  - Isola J
FAU - Lebeau, Annette
AU  - Lebeau A
FAU - Moreno, Aberlardo
AU  - Moreno A
FAU - Penault-Llorca, Frederique
AU  - Penault-Llorca F
FAU - Ruschoff, Josef
AU  - Ruschoff J
FAU - Tomasic, Gorana
AU  - Tomasic G
FAU - van de Vijver, Marc
AU  - van de Vijver M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Algorithms
MH  - Breast Neoplasms/*diagnosis/*genetics
MH  - Genetic Testing/*standards
MH  - *Health Planning Guidelines
MH  - Histocytological Preparation Techniques/methods/standards
MH  - Humans
MH  - Immunohistochemistry/methods/standards
MH  - In Situ Hybridization, Fluorescence
MH  - Quality Control
MH  - Receptor, ErbB-2/*genetics
RF  - 66
EDAT- 2003/02/20 04:00
MHDA- 2003/08/06 05:00
CRDT- 2003/02/20 04:00
PHST- 2003/02/20 04:00 [pubmed]
PHST- 2003/08/06 05:00 [medline]
PHST- 2003/02/20 04:00 [entrez]
AID - 10.1097/01.MP.0000052102.90815.82 [doi]
PST - ppublish
SO  - Mod Pathol. 2003 Feb;16(2):173-82. doi: 10.1097/01.MP.0000052102.90815.82.